Tempus AI (NASDAQ:TEM) Shares Up 5.3% – What’s Next?

Tempus AI, Inc. (NASDAQ:TEM) traded up 5.3% during trading on Monday . The company traded as high as $59.80 and last traded at $60.40. 6,700,130 shares traded hands during trading, a decline of 34% from the average session volume of 10,095,790 shares. The stock had previously closed at $57.39.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on TEM. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and boosted their target price for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Piper Sandler restated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Loop Capital lowered their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Bank of America boosted their price target on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Finally, Wolfe Research started coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $56.36.

Tempus AI Stock Performance

The firm’s 50 day simple moving average is $44.18 and its 200-day simple moving average is $48.29. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insiders Place Their Bets

In other news, CAO Ryan M. Bartolucci sold 13,770 shares of Tempus AI stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $60.00, for a total transaction of $826,200.00. Following the completion of the sale, the chief accounting officer now directly owns 57,237 shares in the company, valued at $3,434,220. The trade was a 19.39 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David R. Epstein sold 620 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total value of $25,922.20. Following the completion of the transaction, the director now owns 27,894 shares in the company, valued at $1,166,248.14. This represents a 2.17 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,037,702 shares of company stock worth $89,449,651.

Institutional Trading of Tempus AI

A number of institutional investors have recently added to or reduced their stakes in the business. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Tempus AI by 166.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock valued at $109,352,000 after purchasing an additional 2,021,394 shares in the last quarter. ARK Investment Management LLC raised its holdings in Tempus AI by 355.0% during the third quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock valued at $134,604,000 after buying an additional 1,855,459 shares in the last quarter. NEA Management Company LLC lifted its position in shares of Tempus AI by 17.8% in the third quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock worth $304,846,000 after buying an additional 813,169 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Tempus AI during the 2nd quarter worth about $8,067,000. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Tempus AI during the 2nd quarter valued at about $5,250,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.